One World Pharma Colombian Cannabis Operator Preparing for Expansion and First Harvest
(LAS VEGAS, NV, February 21, 2019) – One World Pharma Inc. (OTCQB: OWPC), a fully licensed cannabis cultivator with its first operations located in the fertile soil of Popayan, Colombia, is pleased to announce the completion of its recent reverse merger and name change to “One World Pharma Inc.”One World Pharma is well-established in Colombia, which is considered by many to be the most ideal growing location for cannabis, hemp and related products. The nation’s equatorial climate, pro-cannabis government regulations, and talented local population provide the core ingredients to produce the highest yield and quality product for export at the lowest cost, allowing for significant margin regardless of changing market conditions.One World Pharma has been developing relationships and infrastructure in Colombia for two years, working hand in hand with the indigenous population and government officials, preferring to bring a mature business model to the market upon today’s listing as a public company. The Company uniquely holds four government issued licenses for the cultivation of non-psychoactive high THC, cultivation of non-psychoactive low THC, manufacture of cannabis derivatives, and seed use license.“One World Pharma has exceeded our internal expectations as a thriving, rapidly expanding licensed Colombian cannabis producer,” stated Craig Ellens, CEO, One World Pharma, Inc. “The company is ideally situated to capitalize on the Colombian opportunity with an unrivaled production operation in the region. We are monetizing the entire plant in a perfectly synergistic marriage of U.S. based cultivation and manufacturing technology and the unreplicatable environment that Colombia provides.”“We look forward to sharing the results of our first harvest,” added Ellins.
About One World PharmaOne World Pharma Inc. is the U.S. parent company of One World Pharma S.A.S, a fully licensed cannabis and hemp producer with offices and operations in Bogota and Popayan, Colombia. One World Pharma planted its first crop of cannabis in 2018 at its cultivation site in Popayan, Colombia, for research purposes and expects to begin harvesting commercially in the second quarter of 2020. The company intends to supply the highest quality cannabis and hemp derivatives in crude oil, distillate and isolate forms with industrial-scale production to serve global cannabis demand. Its products will be produced and tested to GMP standards.Please note that from time to time the Company may post new information at its website: www.OneWorldPharma.com
One World Pharma Company Contact:
Mimi TekabeOne World Pharma Inc.
One World Pharma Investor Relations & Financial Media:
Toll-Free: (888) 216-3595
Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, risks related to operating in Colombia, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting One World Pharma, please refer to the Company’s Current Report on 8-K filed with the Securities and Exchange Commission on July 12, 2019, which is available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.